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gives rise to uncontrolled proliferation and genome instability in murine models
of Triple Negative Breast Cancer (TNBC). However, the mechanism by which
Mre11 regulates these two processes remains unknown. METHODS: In this
study, we perform a CRISPR based in-vivo murine DDR screen to ﬁrst identify
critical DDR genes that restrain tumor proliferation in a c-Myc driven murine
model of TNBC. We utilized live-cell microscopy and quantitative image based
cytometry in conjunction with a TNBC mammary cell system to assess singlecell fate and cell cycle dynamics of mammary epithelium during oncogene
induction in early neoplasia. RESULTS: Through these studies, we show that
Mre11 mediates a post-mitotic cell cycle exit that maintains genome stability.
We characterize a unique nuclear phenotype associated with Mre11: micronuclei
formation. Mre11 deﬁcient cells are unable to process double strand breaks into
micronuclei and are characterized by a functional defect in interferon signaling
through the cGAS-STING pathway to activate immune cells. CONCLUSIONS:
To date, this is the ﬁrst in-vivo CRISPR DDR screen identifying critical DDR
genes in breast tumorigenesis in a TNBC model. Our work highlights the
importance of Mre11 in early cell cycle checkpoint responses in pre-neoplasia
and deﬁnes a novel p53 tumor suppressor-independent role for Mre11 in innate
immune activation.
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INTRODUCTION: Immediate breast reconstruction after a mastectomy
was reported in 43.3% of female patients in 2014; and has been associated with
improved quality of life and adherence to adjuvant therapies. While there are
many studies regarding immediate breast reconstruction in women, little has
been reported about reconstruction rates and outcomes in male breast cancer.
The purpose of this study is to examine the trends and outcomes of performing
Immediate Breast Reconstruction (IBR) in male breast cancer (MBC) patients
following a mastectomy. METHODS: The National Cancer Database (NCDB)
registry from 2004 to 2014 was used to identify non-metastatic MBC patients
who had a mastectomy with or without an IBR. Patients’ demographics,
readmission, and long-term overall mortality (OM) were compared between IBR
and no-IBR patients. Univariate, multivariate, and propensity score weighted
analyses were used to compare study groups and outcomes. RESULTS: 370
(3.35%) IBR and 10,677 (96.65%) no-IBR patients were identiﬁed. Median
follow-up was 59.63 months. Compared to no-IBR patients, IBR patients
were more likely to be younger (Mean:52, SD:11.7 vs. Mean:65.8, SD:12.8),
be Hispanic, live in a metropolitan county, and have private insurance, less
comorbidities and higher income (P< 0.05). Rates of IBR increased signiﬁcantly
from 1.56% in 2004 to 4.15% in 2014 (P< 0.05). IBR types were 130 (35%)
tissue-based, 96 (26%) implant-based, 42 (11%) combined tissue/implant, and
102 (28%) were non speciﬁed. IBR was not associated with 30-Day readmission
or 90-Day mortality. In the adjusted propensity score weighted analysis, IBR
was not associated with OM for stage I (HR:0.45, P=0.23), stage II (HR:0.95,
P=0.92), or stage III (HR:1.48, P=34) cancer cases. CONCLUSIONS: Our data
suggest that IBR in MBC patients has been increasing over the years, with the
tissue-based IBR as the most common type. There was no association between
IBR and 30-Day readmission rates or overall mortality when compared to MBC
patients who did not receive an IBR.
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INTRODUCTION: Surgery remains standard of care for DCIS. We sought
to understand the factors associated with omission of surgery. We hypothesized
that clinical and biologic factors would most likely inﬂuence non-operative
treatment, and that DCIS patients with favorable biologic factors and who
did not undergo surgery have excellent long-term outcomes. METHODS:
The NCDB was queried from 2004-2017 for women diagnosed with DCIS.

Cochran-Armitage test was used to assess the trend of surgery omission over
year of diagnosis. Multivariable logistic regression was used to determine
characteristics associated with no surgery. Biologically favorable DCIS was
deﬁned as age * 40 years with grade I/II and hormone receptor (HR) positive
disease. Kaplan-Meier curves were estimated to show overall survival (OS)
in this favorable group that did not have surgery, stratiﬁed by Charleson-Deyo
score (CDS). RESULTS: Of the 200,731 women with DCIS, 7,577 (3.77%)
did not have surgery. There was no difference over time in the proportion of
patients who omitted surgery. Older age, black race and uninsured status were
associated with omission of surgery (OR 1.02 [95% CI 1.02–1.02] per year
increase in age, OR 1.57 [95% CI 1.47-1.68] vs white race and OR 2.48 [95% CI
2.16-2.85] vs those with private insurance respectively). There was no consistent
association between lesion size and omission of surgery; lesions *5cm were
more likely to not have surgery as compared to those < 1cm (OR 1.59, 95% CI
1.35 to 1.86). A consistent trend was lacking for the association of increasing
CDS with omission of surgery. Lower grade and HR positive DCIS were not
associated with omission of surgery. In patients with biologically favorable
DCIS who did not have surgery, the 5-year OS was 97% in patients with CDS
of 0 vs 82% in patients with a CDS of 3+ (p< 0.01). CONCLUSIONS: The
proportion of patients with DCIS not treated with surgery has remained stable
over time. Disparities, such as race and insurance status, appeared to be more
strongly associated with omission of surgery compared to clinical or biologic
factors. In a population of biologically favorable DCIS not treated with surgery,
those with few comorbidities have excellent 5-year OS.
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INTRODUCTION: It has been suggested that sentinel lymph node biopsy
(SLNB) can be omitted in elderly women with clinically lymph node-negative,
hormone receptor positive (HR+) breast cancer. These recommendations are
based on retrospective studies of women who underwent SLNB. To date these
guidelines are not frequently followed. The aim of this study was to assess
the long-term outcomes of breast cancer patients where SLNB was omitted.
METHODS: Single institution retrospective review of patients with clinically
lymph node-negative invasive breast cancer undergoing surgery as primary
initial therapy without SLNB from 1998-2015. Patient and tumor characteristics,
including treatment and recurrence data, were collected. RESULTS: We
identiﬁed 128 patients of whom the mean age was 78.8 years (range: 37 to
98), mean tumor size was 1.6 cm, and 92 (72%) were invasive ductal type.
HR+ tumors accounted for 94.6%. Breast conserving surgery was performed in
95.3% of patients and mastectomy in 4.7%. Final pathology revealed multifocal
disease in 26 (20%) cases, and lymphovascular invasion was present in 32
(25%) cases. Adjuvant administered therapy was 3.8% chemotherapy, 73.3%
hormonal therapy, and 51.9% radiation Using a well-known online nomogram
for predicting SLN positivity, we calculated an expected 25.1% rate for this
cohort. At a median follow-up of 5.6 years, there were 13 (10%) recurrences
of which only 4 (3%) occurred in the axilla (including 2 with synchronous
relapses elsewhere). Mean time to axillary recurrence was 3.5 years. There
was no statistically signiﬁcant difference in overall recurrence or axillaryspeciﬁc recurrence for ages 50-69 (n=12) vs *70 (n=110); (p=0.61 and p=0.34,
respectively).CONCLUSIONS: These ﬁndings demonstrate that SLNB can be
safely omitted in patients as young as 50 with < 2cm, HR+, clinically lymph
node-negative breast cancers without untoward patient outcomes, despite
predictors that may suggest the presence of nodal metastasis.

